New Copper Nanozyme Shows Powerful Tumor Suppression with High Precision

Why It Matters

The advance delivers a scalable, high‑efficiency nanozyme that merges therapy and imaging, addressing precision and safety gaps in current cancer treatments and opening a commercial pathway for nanomedicine platforms.

Key Takeaways

• Cu‑N₂‑CDs increase hydroxyl radical generation 3.62× faster
• H₂O₂ adsorption rises 3.49× with unsaturated Cu‑N₂ sites
• In vivo studies show markedly stronger tumor suppression than Cu‑N₄
• Nanozyme enables deep tumor imaging while maintaining biosafety
• One‑step hydrothermal synthesis simplifies production of single‑atom catalysts

Pulse Analysis

The quest for precision oncology has driven researchers toward nanocatalysts that can convert the tumor microenvironment into a therapeutic advantage. Conventional copper nanozymes, while promising, suffer from limited substrate binding and complex synthesis, curbing their clinical translation. The recent breakthrough from the Hefei Institutes of Physical Science introduces a coordinatively unsaturated copper single‑atom nanozyme that overcomes these barriers. By leveraging a ligand‑chelation strategy with EDTA, the team produced carbon‑dot‑supported Cu‑N₂ sites in a single hydrothermal step, offering a scalable route to high‑performance catalysts.

The unsaturated Cu‑N₂ configuration creates a high‑spin, electron‑rich copper center that shifts the d‑band upward, dramatically improving H₂O₂ adsorption—up to 3.49 times higher than saturated Cu‑N₄ analogues. This enhanced adsorption, combined with a narrowed band gap, accelerates electron transfer and boosts hydroxyl radical (·OH) generation by 3.62‑fold, as confirmed by in‑situ electron paramagnetic resonance and density‑functional‑theory calculations. Dual enzyme‑like activity, mimicking peroxidase and glutathione peroxidase, enables the nanozyme to deplete antioxidants and amplify oxidative stress selectively within tumors.

Preclinical results demonstrate that Cu‑N₂‑CDs not only reduce cancer‑cell viability more effectively than Cu‑N₄ but also achieve superior tumor suppression in animal models, all while preserving biosafety. The carbon‑dot platform also provides intrinsic fluorescence, allowing real‑time imaging to guide therapy delivery. This convergence of catalytic potency and diagnostic capability positions the nanozyme as a candidate for theranostic applications, potentially accelerating the pipeline from bench to bedside. As the market for nanomedicine expands, such single‑atom catalysts could attract investment from biotech firms seeking next‑generation, precision‑engineered cancer treatments.